FDA Approves Additional Indication for Pemetrexed in Combination

On December 19, 2022, the U.S. Food and Drug Administration (FDA) approved an additional indication for pemetrexed in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer, with no epidermal growth factor receptor or anaplastic large-cell lymphoma kinase genomic tumor aberrations.

For more information, read Eagle Pharmaceuticals' press release.

Posted 12/21/2022